rugmaker Seeks Approval For China s First Biosimilar Ozempic聽A drugmaker in China has developed a biosimilar version of Novo Nordisk s NOVOb.CO popular diabetes drug Ozempic and applied for approval to sell it there, in a potential challenge to Novo s expansion plans in the country. Hangzhou Jiuyuan Gene Engineering said on Wednesday in a post on its official social media account that it was seeking approval to sell the drug, which it hydro flask cup calls Jiyoutai, to control blood sugar in patients with type 2 diabetes. Silver and Burger, 4/3 Modern Healthcare:How Risant Health Fits Into Value-Based Care M Mmpn Global Fund to Fight AIDS, Tuberculosis and Malaria Awards First Three Checks| 欢迎光临 深圳教育网 (http://szjyw.com/) | Powered by Discuz! X3.4 |